MA56607A1 - Méthodes de traitement de troubles dépressifs - Google Patents

Méthodes de traitement de troubles dépressifs

Info

Publication number
MA56607A1
MA56607A1 MA56607A MA56607A MA56607A1 MA 56607 A1 MA56607 A1 MA 56607A1 MA 56607 A MA56607 A MA 56607A MA 56607 A MA56607 A MA 56607A MA 56607 A1 MA56607 A1 MA 56607A1
Authority
MA
Morocco
Prior art keywords
methods
depressive disorders
treating depressive
compound
present
Prior art date
Application number
MA56607A
Other languages
English (en)
Inventor
Gregory N Beatch
Cynthia Louise Harden
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of MA56607A1 publication Critical patent/MA56607A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Selon certains modes de réalisation, la présente invention concerne des méthodes et des utilisations pour traiter des troubles dépressifs chez un être humain, les méthodes comprenant l'administration par voie orale d'une quantité thérapeutiquement efficace de n-[4-(6-fluoro-3,4-dihydro-1h-isoquinolin-2-yl)-2,6-diméthylphényl]-3,3-diméthylbutanamide (composé a), à la personne nécessitant un tel traitement. La présente invention concerne également diverses méthodes améliorées de thérapie et d'administration du composé a.
MA56607A 2019-11-08 2020-11-06 Méthodes de traitement de troubles dépressifs MA56607A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962932724P 2019-11-08 2019-11-08
PCT/US2020/059481 WO2021092439A1 (fr) 2019-11-08 2020-11-06 Méthodes de traitement de troubles dépressifs

Publications (1)

Publication Number Publication Date
MA56607A1 true MA56607A1 (fr) 2022-10-31

Family

ID=73643360

Family Applications (1)

Application Number Title Priority Date Filing Date
MA56607A MA56607A1 (fr) 2019-11-08 2020-11-06 Méthodes de traitement de troubles dépressifs

Country Status (19)

Country Link
US (2) US12178811B2 (fr)
EP (1) EP4054580A1 (fr)
JP (2) JP2022553569A (fr)
KR (1) KR20220098746A (fr)
CN (1) CN114667146A (fr)
AU (1) AU2020380961A1 (fr)
BR (1) BR112022008580A2 (fr)
CA (1) CA3155812A1 (fr)
CL (1) CL2022001102A1 (fr)
CO (1) CO2022008001A2 (fr)
CR (1) CR20220250A (fr)
GE (2) GEAP202415942A (fr)
IL (1) IL292678A (fr)
MA (1) MA56607A1 (fr)
MX (1) MX2022005490A (fr)
PE (1) PE20221766A1 (fr)
PH (1) PH12022551110A1 (fr)
TW (1) TW202128162A (fr)
WO (1) WO2021092439A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3155812A1 (fr) 2019-11-08 2021-05-14 Cynthia Louise HARDEN Methodes de traitement de troubles depressifs
CA3159876A1 (fr) 2019-12-06 2021-06-10 James MURROUGH Procede de traitement avec des activateurs de canaux kcnq
EP4291185A1 (fr) * 2021-02-09 2023-12-20 Xenon Pharmaceuticals Inc. Thérapie conjointe pour le traitement de crises épileptiques
CN116847843A (zh) 2021-02-09 2023-10-03 泽农医药公司 用于治疗快感缺乏的电压门控的钾通道开放剂

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3639385A (en) 1968-07-26 1972-02-01 Eastman Kodak Co Heterocyclic monoazo compounds from n n-diaralkyl anilines and polyester textile materials dyed therewith
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4181803A (en) 1973-12-14 1980-01-01 Eisai Co., Ltd. Propiophenone derivatives and preparation thereof
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
DE3369315D1 (en) 1982-10-27 1987-02-26 Degussa Derivatives of 2-amino-3-acylamino-6-benzylamino pyridine with an anti-epileptic activity
DE3337593A1 (de) 1982-10-27 1984-05-03 Degussa Ag, 6000 Frankfurt 2-amino-3-acylamino-6-benzylamino-pyridin-derivate mit antiepileptischer wirkung
DE3665538D1 (en) 1985-01-23 1989-10-19 Asta Pharma Ag Synergistic combination of flupirtin and non-steroidal anti-phlogistics
DE3604575A1 (de) 1985-02-23 1986-08-28 Degussa Ag, 6000 Frankfurt Kombination von flupirtin und anticholinergisch wirkenden spasmolytika
DE3663775D1 (en) 1985-02-23 1989-07-13 Asta Pharma Ag Combination of flupirtin with spasmolytics having an anticholinergic effect
JP2583067B2 (ja) 1987-08-04 1997-02-19 住友化学工業株式会社 モノアゾ化合物およびそれを用いて疎水性繊維材料を染色または捺染する方法
GB8800199D0 (en) 1988-01-06 1988-02-10 Beecham Group Plc Pharmaceutical preparation
MC2029A1 (fr) 1988-05-16 1990-04-25 Asta Pharma Ag (n-heterocyclyl)-3 diamino-2,6 pyridines substituees et leurs n-oxydes,preparation de ces composes et leur application comme medicaments
US5629307A (en) 1989-10-20 1997-05-13 Olney; John W. Use of ibogaine in reducing excitotoxic brain damage
US6004945A (en) 1990-05-10 1999-12-21 Fukunaga; Atsuo F. Use of adenosine compounds to relieve pain
IN172468B (fr) 1990-07-14 1993-08-14 Asta Medica Ag
US5643921A (en) 1990-09-26 1997-07-01 E.R. Squibb & Sons, Inc. Cardiopulmonary bypass and organ transplant using a potassium channel activator
US5234947A (en) 1991-11-07 1993-08-10 New York University Potassium channel activating compounds and methods of use thereof
DE4200259A1 (de) 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
US5262419A (en) 1992-06-11 1993-11-16 E. R. Squibb & Sons, Inc. Method for the prophylaxis and/or treatment of ulcerative gastrointestinal conditions using a potassium channel activator
CA2115792C (fr) 1993-03-05 2005-11-01 David J. Mayer Methode de traitement de la douleur
US5428039A (en) 1994-02-20 1995-06-27 The Center For Innovative Technology Method for electively achieving reversible hyperpolarized cardiac arrest
AU8071894A (en) 1994-09-22 1996-04-09 Jonathan M Licht Compositions useful for the preparation of medicines for treating a variety of intractable disorders
US5679706A (en) 1994-09-30 1997-10-21 Bristol-Myers Squibb Company Combination of a potassium channel activator and an antiarrhythmic agent
MX9703988A (es) 1994-12-12 1998-02-28 Omeros Med Sys Inc SOLUCIaN Y MÉTODO DE IRRIGACIaN PARA LA INHIBICIaN DEL DOLOR, LA INFLAMACIaN Y ES ESPASMO.
DE19539861A1 (de) 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
DE19701694A1 (de) 1997-01-20 1998-07-23 Asta Medica Ag Neue Modifikationen des 2-Amino-4-(4-fluorbenzylamino)-l-ethoxycarbonyl-aminobenzen sowie Verfahren zu ihrer Herstellung
US5760007A (en) 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
US6218411B1 (en) 1997-08-08 2001-04-17 Chugai Seiyaku Kabushiki Kaisha Therapeutics for diabetic complications
US6265417B1 (en) 1997-12-18 2001-07-24 Abbott Laboratories Potassium channel openers
US6593335B1 (en) 1997-12-18 2003-07-15 Abbott Laboratories Potassium channel openers
US6211171B1 (en) 1998-05-19 2001-04-03 Dalhousie University Use of antidepressants for local analgesia
JP3441970B2 (ja) 1998-06-30 2003-09-02 株式会社サミー 豆腐の製造方法及び製造装置
US6395736B1 (en) 1998-12-14 2002-05-28 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
US6281211B1 (en) 1999-02-04 2001-08-28 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
GB9903476D0 (en) 1999-02-17 1999-04-07 Zeneca Ltd Therapeutic agents
US6451857B1 (en) 1999-03-10 2002-09-17 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
WO2000055137A1 (fr) 1999-03-17 2000-09-21 Signal Pharmaceuticals, Inc. Composes et techniques de modulation des recepteurs des oestrogenes
AT409083B (de) 1999-04-01 2002-05-27 Sanochemia Pharmazeutika Ag Pharmazeutische, tolperison enthaltende zubereitung zur oralen verabreichung
US6610324B2 (en) 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
GB9915414D0 (en) 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
EP1200073B1 (fr) 1999-07-06 2007-01-10 Eli Lilly And Company ANTAGONISTES SELECTIFS DU RECEPTEUR iGluR 5? UTILISES DANS LE TRAITEMENT DE LA MIGRAINE
US6472165B1 (en) 1999-08-03 2002-10-29 Arzneimittelwerk Dresden Gmbh Modulatory binding site in potassium channels for screening and finding new active ingredients
EP1208085B1 (fr) 1999-08-04 2007-12-05 Icagen, Inc. Benzanilides comme ouvreurs de canaux potassiques
US6495550B2 (en) 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
BR0012934A (pt) 1999-08-04 2003-07-29 Icagen Inc Processos para a redução de dor e de ansiedade
US6117900A (en) 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
US6383511B1 (en) 1999-10-25 2002-05-07 Epicept Corporation Local prevention or amelioration of pain from surgically closed wounds
US6538004B2 (en) 2000-03-03 2003-03-25 Abbott Laboratories Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers
US20020015730A1 (en) 2000-03-09 2002-02-07 Torsten Hoffmann Pharmaceutical formulations and method for making
US6348486B1 (en) 2000-10-17 2002-02-19 American Home Products Corporation Methods for modulating bladder function
US6589986B2 (en) 2000-12-20 2003-07-08 Wyeth Methods of treating anxiety disorders
US6469042B1 (en) 2001-02-20 2002-10-22 Bristol-Myers Squibb Company Fluoro oxindole derivatives as modulators if KCNQ potassium channels
AR033095A1 (es) 2001-04-04 2003-12-03 Wyeth Corp Metodos para el tratamiento de motilidad gastrica hiperactiva
GB0121214D0 (en) 2001-08-31 2001-10-24 Btg Int Ltd Synthetic method
WO2003068769A1 (fr) 2002-02-12 2003-08-21 Pfizer Inc. Composes non-peptidiques influant sur l'action de la gnrh
US6984647B2 (en) 2002-05-17 2006-01-10 Janssen Pharmaceutica N.V. Aminotetralin-derived urea modulators of vanilloid VR1 receptor
WO2003106454A1 (fr) 2002-06-12 2003-12-24 Orchid Chemicals & Pharmaceuticals Ltd Derives de 1h-isoquinoline-oxazolidinone, et leur utilisation comme agents antibacteriens
AUPS312602A0 (en) 2002-06-21 2002-07-18 James Cook University Organ arrest, protection, preservation and recovery
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
AU2003294441A1 (en) 2002-11-22 2004-06-18 Bristol-Myers Squibb Company 1-aryl-2-hydroxyethyl amides as potassium channel openers
AU2003303484C1 (en) 2002-12-23 2012-06-14 Icagen, Inc. Quinazolinones as potassium channel modulators
PT1578740E (pt) 2002-12-27 2007-05-31 Lundbeck & Co As H Derivados de 1, 2, 4-triaminobenzeno úteis para tratamento de distúrbios do sistema nervoso central
WO2004080950A1 (fr) 2003-03-14 2004-09-23 H. Lundbeck A/S Derives d'aniline substitues
SG157231A1 (en) 2003-03-21 2009-12-29 Lundbeck & Co As H Substituted p-diaminobenzene derivatives
WO2004096767A1 (fr) 2003-04-25 2004-11-11 H. Lundbeck A/S Derives indole et indoline substitues
AU2004243444A1 (en) 2003-05-27 2004-12-09 Altana Pharma Ag Pharmaceutical combinations of a proton pump inhibitor and a compound which modifies gastrointestinal motility
US20050070570A1 (en) 2003-06-18 2005-03-31 4Sc Ag Novel potassium channels modulators
JP2007505142A (ja) 2003-09-10 2007-03-08 セダーズ−シナイ メディカル センター 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達
US7799832B2 (en) 2003-10-23 2010-09-21 Valeant Pharmaceuticals North America Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
DE10359335A1 (de) 2003-10-23 2005-05-25 Viatris Gmbh & Co. Kg Kombinationen aus Kaliumkanalöffnern und Natriumkanalinhibitoren oder Natriumkanal beeinflussenden Wirkstoffen zur Behandlung von Schmerzzuständen
ES2235626B1 (es) 2003-11-10 2006-11-01 Almirall Prodesfarma, S.A. Formas de administracion masticables, no comprimidas dosificadas individualmente.
US8236861B2 (en) 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
TWI357901B (en) 2004-03-12 2012-02-11 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivati
WO2005100349A2 (fr) 2004-04-13 2005-10-27 Icagen, Inc. Pyridines polycycliques en tant que modulateurs de canal ionique du potassium
BRPI0510593A (pt) 2004-05-03 2007-11-20 Univ Duke composições para afetar a perda de peso
UA89503C2 (uk) 2004-09-13 2010-02-10 Х. Луннбек А/С Заміщені похідні аніліну
WO2006054513A1 (fr) 2004-11-19 2006-05-26 Kissei Pharmaceutical Co., Ltd. Agent préventif ou thérapeutique pour la douleur neuropathique
EP1688141A1 (fr) 2005-01-31 2006-08-09 elbion AG Utilisation de flupirtine pour le traitement de la vessie hyperactive et des maladies associées et pour le traitement du syndrome du colon irritable
WO2006092143A1 (fr) 2005-03-03 2006-09-08 H. Lundbeck A/S Derives de pyridine substitues
EP1891089B1 (fr) 2005-06-02 2014-11-05 Merck Sharp & Dohme Corp. Inhibiteurs de protease du VHC en combinaison avec des aliments
US7683058B2 (en) 2005-09-09 2010-03-23 H. Lundbeck A/S Substituted pyrimidine derivatives
EP2012769A1 (fr) 2006-05-02 2009-01-14 Rundfeldt, Chris Activateurs de canaux potassiques pour la prévention et le traitement de la dystonie et des systèmes assimilés à la dystonie
US8293911B2 (en) * 2006-08-23 2012-10-23 Valeant Pharmaceuticals International Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
WO2008066900A1 (fr) 2006-11-28 2008-06-05 Valeant Pharmaceuticals International Analogues de 1,4-diamino rétigabine bicycliques en tant que modulateurs de canaux potassiques
US20090018154A1 (en) 2007-05-17 2009-01-15 Endo Pharmaceuticals, Inc., A Corporation Of Delaware Opioid and methods of making and using the same
AR070513A1 (es) * 2007-08-01 2010-04-14 Lundbeck & Co As H Uso de abridores de canales de potasio kcnq para reducir los sintomas o tratar desordenes o afecciones en las cuales se encuentra anulado el sis-tema dopaminergico como por ejemplo esquizofrenia y trastorno depresivo mayor
WO2009074594A1 (fr) * 2007-12-11 2009-06-18 Neurosearch A/S Nouveaux dérivés de 2-éthyl-méthyl-amino-3-amido-6-amino-pyridine utiles en tant d'activateurs de canaux potassiques
US20100323016A1 (en) 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
CN102802615A (zh) 2010-01-20 2012-11-28 葛兰素集团有限公司 新瑞替加滨组合物
WO2013067591A1 (fr) 2011-11-10 2013-05-16 Relevare Australia Pty Ltd Formulations topiques pour gestion de la douleur
US10500216B2 (en) 2011-11-18 2019-12-10 Corcept Therapeutics, Inc. Optimizing mifepristone absorption
US9248122B2 (en) 2012-11-28 2016-02-02 Grünenthal GmbH Heteroquinoline-3-carboxamides as KCNQ2/3 modulators
MA51881B1 (fr) * 2018-02-20 2023-08-31 H Lundbeck As Dérivés d'alcool utilisés en tant qu'agents d'ouverture du canal potassique kv7
IL319015A (en) 2018-05-11 2025-04-01 Xenon Pharmaceuticals Inc Methods for improving bioavailability and exposure of voltage-gated potassium channel openers
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
CA3155812A1 (fr) 2019-11-08 2021-05-14 Cynthia Louise HARDEN Methodes de traitement de troubles depressifs
CA3159876A1 (fr) 2019-12-06 2021-06-10 James MURROUGH Procede de traitement avec des activateurs de canaux kcnq
US20210213009A1 (en) 2019-12-13 2021-07-15 Xenon Pharmaceuticals Inc. Methods of treating pain
EP4291185A1 (fr) 2021-02-09 2023-12-20 Xenon Pharmaceuticals Inc. Thérapie conjointe pour le traitement de crises épileptiques
CN116847843A (zh) 2021-02-09 2023-10-03 泽农医药公司 用于治疗快感缺乏的电压门控的钾通道开放剂
JP7294734B2 (ja) 2021-10-27 2023-06-20 シャンハイ ジムン バイオファーマ，インコーポレーテッド カリウムチャネル調節剤としての化合物ならびにその調製および応用

Also Published As

Publication number Publication date
JP2026001049A (ja) 2026-01-06
PH12022551110A1 (en) 2024-02-26
CL2022001102A1 (es) 2023-01-27
IL292678A (en) 2022-07-01
US20250108044A1 (en) 2025-04-03
CO2022008001A2 (es) 2022-06-10
WO2021092439A1 (fr) 2021-05-14
AU2020380961A1 (en) 2022-05-26
US20210161886A1 (en) 2021-06-03
NZ787838A (en) 2025-08-29
MX2022005490A (es) 2022-08-10
CN114667146A (zh) 2022-06-24
GEAP202415942A (en) 2024-10-28
CR20220250A (es) 2022-08-19
JP2022553569A (ja) 2022-12-23
US12178811B2 (en) 2024-12-31
BR112022008580A2 (pt) 2022-08-09
TW202128162A (zh) 2021-08-01
CA3155812A1 (fr) 2021-05-14
PE20221766A1 (es) 2022-11-11
KR20220098746A (ko) 2022-07-12
GEP20257732B (en) 2025-02-10
EP4054580A1 (fr) 2022-09-14

Similar Documents

Publication Publication Date Title
MA56607A1 (fr) Méthodes de traitement de troubles dépressifs
RU2498988C2 (ru) Ингибиторы активности протеинтирозинкиназы
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
MA52569B1 (fr) Méthodes pour améliorer la biodisponibilité et l'exposition d'un activateur de canal potassique voltage-dépendant
MA25809A1 (fr) Derives d'arylmethylamine pour usage comme inhibiteurs de tryptase
MA51627B1 (fr) Benzofurane, benzopyrrole, benzothiophène substitués et inhibiteurs du complément structurellement apparentés
TNSN07063A1 (fr) Utilisations therapeutiques d'inhibiteurs de rtp801
ATE119520T1 (de) Derivate von hydroxaminsäure und von n- hydroxyharnstoff sowie ihre verwendung.
DE60125541D1 (de) Neue nicht psychotropische cannabinoide
DE60322436D1 (de) Verabreichung von capsaicinoiden
EA199900669A1 (ru) Промежуточные соединения для получения замещенных n-[аминоиминометил или аминометил)фенил]пропиламидов
DE60140871D1 (de) Arylmethylamin-derivate zur verwendung als inhibitoren von tryptase
HUP9802971A1 (hu) Az MMP-inhibitorok alkalmazása a szemben történő érképződés kezelésére
EP0699439A3 (fr) Traitement des maladies provoquées par des troubles des glandes sébacés avec l'emploi d'inhibiteurs de l'acyl CoA cholestérol acyl transferase
BG98827A (bg) Фармацевтичен състав и метод за неговото получаване
NO20044530L (no) Fremgangsmate for behandling av kognitive forstyrrelser
ATE499933T1 (de) Verwendung von betain zur behandlung von claudicatio intermittens
UA42719C2 (uk) Сполуки, композиції та способи, які інгібують протеази, для лікування та профілактики імуномедіаторних запальних хвороб
EA200400302A1 (ru) Способ лечения первичной бессонницы
DE69512940D1 (de) N-hydroxy-harnstoff-derivate als entzündunghemmende mittel
MA27539A1 (fr) Nouvelle combinaison synergique contenant du roflumilast et du formoterol
DE69924979D1 (de) Behandlung von chronischen schmerzen
MA61730A1 (fr) Thérapie conjointe pour le traitement de crises épileptiques
EA200401295A1 (ru) Статиновая терапия для усиления поддержания когнитивной функции
MA56958A1 (fr) Utilisation d'un agent d'ouverture du canal potassique kv7 pour le traitement de la douleur